- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00540072
Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
November 13, 2019 updated by: Cubist Pharmaceuticals LLC
A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE
Study Overview
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provide signed and dated informed consent.
- Adults, 18 years of age or older of either gender and of any race weighing up to 150 kg. Female patients of childbearing potential MUST be nonpregnant (confirmed by negative serum pregnancy test), nonlactating, and must be willing to practice reliable birth control measures during and for at least 30 days after treatment with study drug(s).
- Have a new pulmonary infiltrate on chest radiograph.
Exhibit at least two of the following clinical symptoms of pneumonia on history or physical:
- Cough
- Production of purulent sputum or change in character of sputum
- Auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation (dullness to percussion, bronchial breath sounds, or egophony)
- Dyspnea or tachypnea
- Documented fever, defined as body temperature >38.0 ºC (100.4 ºF) taken orally; >38.5 ºC (101.2 ºF) tympanically; or >39.0 ºC (102.2 ºF) rectally or hypothermia, defined as core body temperature of <35.0 ºC (95.0 ºF)
- An elevated total peripheral white blood cell count (WBC >10,000/mm3); or >15% immature neutrophils (bands), regardless of total peripheral white count; or leukopenia with total WBC <4500/mm3.
- Hypoxemia with a PO2 < 60 mmHg (on room air) or O2 saturation <90% on room air
- Pneumonia which requires hospitalization and intravenous therapy for at least 5 days.
- Willingness to participate in this study and to complete all follow-up assessments.
Exclusion Criteria:
- Patients with Grade V pneumonia (based on Fine Score; Attachment 8).
- Patients in respiratory failure or incipient respiratory failure if the patient is not a candidate for mechanical ventilation (for any reason).
Any of the following pulmonary conditions that may preclude interpretation of study results:
- Cystic fibrosis
- Primary lung cancer or another malignancy metastatic to the lungs
- Known bronchial obstruction or a history of post-obstructive pneumonia
- Known or suspected active tuberculosis.
- Severe shock (systolic blood pressure <90 mm Hg for >30 minutes not corrected by fluid bolus).
- Clinical evidence of bacterial meningitis (based on lumbar puncture results).
- Severe renal impairment (calculated creatinine clearance <30 mL/min).
- Moribund clinical condition: high likelihood of death during the first 48 hours.
- If HIV positive, known CD4 counts <200/mm3 or evidence of Pneumocystis carinii pneumonia.
- Inability to tolerate ceftriaxone or history of allergy to beta-lactam antibiotics (history of rash alone will not exclude a patient).
- Any individual previously treated with a potentially effective anti-infective agent for > 24 hours (or one dosing day) within 72 hours of enrollment, or prior treatment with any investigational drug (including experimental biologic agents) in previous 30 days or prior therapy with daptomycin.
- Patients who must continue HMG-CoA reductase inhibitor therapy (e.g., simvastatin, lovastatin, etc.) during the study treatment period.
- Anticipation that a second non-protocol systemic antibiotic will be required.
- Induction chemotherapy within 2 weeks prior to enrollment (or exogenous therapies which are anticipated to result in PMN counts of <200 mm3 during Treatment Phase), or patients with severe neutropenia (<200 PMN cells/mm3).
- Patients considered unreliable to return for visits or to comply with study procedures.
- Progressive neoplastic disease (Note: patients with malignancies in remission are eligible).
- Women who are pregnant or nursing/lactating.
- Patients presenting with nosocomial pneumonia (i.e., <14 days after discharge from a skilled nursing facility or hospital with an initial hospitalization of >=3 days duration).
- Clinical suspicion of Legionella pneumonia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 30, 2001
Primary Completion (Actual)
February 27, 2002
Study Completion (Actual)
February 27, 2002
Study Registration Dates
First Submitted
October 4, 2007
First Submitted That Met QC Criteria
October 4, 2007
First Posted (Estimate)
October 5, 2007
Study Record Updates
Last Update Posted (Actual)
November 14, 2019
Last Update Submitted That Met QC Criteria
November 13, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAP-CAP-00-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia, Bacterial
-
Evopoint Biosciences Inc.RecruitingHospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaUnited States, Spain, France, Israel
-
Merck Sharp & Dohme LLCCompletedHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial PneumoniaMexico, Brazil, China, France, Philippines, Romania, Russian Federation, Ukraine
-
Omnix Medical LtdNot yet recruitingVentilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia
-
Massachusetts General HospitalUnited States Agency for International Development (USAID)UnknownInfections - Bacterial | Pneumonia - BacterialPakistan
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Zai Lab (Hong Kong), Ltd.RecruitingCommunity-acquired Bacterial PneumoniaUnited States
-
Melinta Therapeutics, Inc.Biomedical Advanced Research and Development AuthorityTerminatedCommunity-acquired Bacterial PneumoniaSpain, United States, Philippines, Hungary, United Kingdom, Bulgaria
-
Melinta Therapeutics, Inc.CompletedCommunity-Acquired Bacterial PneumoniaUnited States, Canada
-
Fundación Pública Andaluza para la gestión de la...European CommissionCompletedVentilator-associated Bacterial PneumoniaSpain, Italy, Greece
-
Albany Medical CollegeForest Laboratories; Albany College of Pharmacy and Health SciencesCompletedCommunity Acquired Bacterial PneumoniaUnited States
Clinical Trials on daptomycin
-
Cubist Pharmaceuticals LLCTerminatedWound Infections
-
Cubist Pharmaceuticals LLCCompletedGram Positive Infection | Concurrent Antibiotic TreatmentUnited States
-
Cubist Pharmaceuticals LLCCompletedBacteremia | Bacterial Endocarditis
-
University Hospital, CaenCompletedPeritoneal InfectionFrance
-
Merck Sharp & Dohme LLCCompleted
-
Cubist Pharmaceuticals LLCTerminatedGram-Positive Bacterial Infections
-
University of Maryland, BaltimoreCubist Pharmaceuticals LLCCompletedFasciitis, Necrotizing | Fournier's Gangrene | Severe Necrotizing Skin and Soft Tissue InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompleted
-
Cubist Pharmaceuticals LLCCompletedGram-positive Bacterial InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompleted